Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 35 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/1/1998


1.		Phase III Randomized Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) vs Fludarabine (FAMP) for Pretreated B-Cell Chronic Lymphocytic Leukemia (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 79								EORTC-06942

Last Modified: 7/24/2006 First Published: 3/1/1999


2.		Phase III Randomized Study of Daily Versus Weekly Cladribine in Patients with Hairy Cell Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other				SWS-SAKK-32/98 EU-98074, NCT00003746

Last Modified: 3/1/2000 First Published: 12/1/1999


3.		Phase I/II Study of Cladribine Plus Interferon in Patients with Advanced Low Grade Lymphoid Malignancies (Summary Last Modified 03/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				NU-93H4 NCI-G99-1635

Last Modified: 7/12/2007


4.		phase I/II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) as a Pretransplant Immunosuppressive Agent to Prevent Graft Failure in Patients with Hematologic Malignancies Undergoing Transplant with T-Cell-Depleted Marrow from HLA-Haploidentical Donors (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care				Closed				5 to 50				NCI				FHCRC-126.8 NCI-T91-0013D, T91-0013

Last Modified: 5/1/1998


5.		Phase I/II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Adults with Acute Nonlymphoblastic Leukemia (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				17 and over								MSKCC-91094 NCI-V91-0185

Last Modified: 5/1/1998


6.		Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Stage III/IV, Low- or Intermediate-Grade, Follicular non-Hodgkin's Lymphoma Previously Untreated with Chemotherapy (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 70								SWS-SAKK-39/93 EU-93012

Last Modified: 5/1/1998


7.		Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) and Chlorambucil for B-Cell Chronic Lymphocytic Leukemia Previously Untreated with Chemotherapy (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCCTG-938151 NCCTG-93-81-51

Last Modified: 5/1/1998


8.		Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Progressive or Recurrent Malignant Glioma (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 18								UCCRC-7154 NCI-V94-0451

Last Modified: 5/1/1998


9.		Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Residual and Recurrent Primary CNS Malignancies (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 18								MSKCC-94038 NCI-V94-0475

Last Modified: 4/12/2006


10.		Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Hairy Cell Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				any age								SWS-SAKK-32/93 EU-94037

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute